For peptide microarray-based epitope mappings, an antigen sequence is translated into overlapping peptides. To save costs, the peptide-peptide overlap is frequently reduced to e.g. 10 or 11 amino acids with 15mer peptides, as provided by most commercial suppliers. The peptide-peptide overlap, however, plays an important role for epitope prediction. A reduced peptide-peptide overlap hampers the exact identification of conserved core motifs, the unambiguous itemization of neighbored epitopes in polyclonal samples, or the discrimination of non-specific binders from real epitopes.
Due to our proprietary laser printer-based on-chip synthesis, PEPperPRINT is able to routinely translate antigens into peptide microarrays with a maximum peptide-peptide overlap, e.g. 14 amino acids with 15mer peptides (equals a shift of 1), to provide the maximum amount of epitope coverage and prediction at reasonable costs.

For further information please read the application note “Comparison of High Resolution PEPperMAP® Epitope Mappings with Low Resolution Epitope Mappings” available on the website

PEPperCIP epitope mapping

High resolution linear Epitope Mapping is based on an antigen translated into 15 aa overlapping peptides with maximum peptide-peptide overlap of 14 aa (shift 1). The peptides are directly synthesized on the glass slides. The array is subsequently stained with the target antibody that binds to its specific epitope and a secondary antibody that has a fluorescence label. An image of the array is taken with a microarray scanner. Since PEPperPRINT prints spot duplicates, each signal appears in a double row. After data acquisition, the PepSlide® Analyzer software immediately calculates the common motif in the peptide hits, which is the epitope of the target antibody.
On the left two examples of such an epitope mapping are shown, a monoclonal sample binding to a single epitope and a polyclonal sample binding to multiple epitopes. Each array is surrounded by HA (red) and FLAG (green) control peptides.


  • Zedira offers a huge portfolio of reliable specialist transglutaminase related products meant to catalyze research and development, both in academia and industry.


  • imageReversibly acting transglutaminase 2 inhibitors: drug candidates for the treatment of fibrosis
  • Zedira supports Gordon Research Conference
  • imagePress release: Zedira announces ISO 9001:2015 certification
  • imageZedira communication: Joint poster presentation on “Feasibility of a new automated FXIII activity assay”
  • imageArtikel in DZG Aktuell 01/2019 über die klinische Wirksamkeitsstudie unseres potentiellen Zöliakie Medikaments (deutsch)
  • imagePreview: Catalogue Editorial 2019
  • Press release: Dr. Falk Pharma and Zedira announce start of the phase 2a proof of concept study of ZED1227 for the treatment of celiac disease
  • Artikel in DLG-Lebensmittel – 06/2017 zur Bestimmung von Transglutaminase in Lebensmitteln (deutsch)
  • Zedira publication: Microbial Transglutaminase Used in Bread Preparation at Standard Bakery Concentrations Does Not Increase Immunodetectable Amounts of Deamidated Gliadin
  • Pressemitteilung: Dr. Falk Pharma und Zedira geben den Abschluss der Phase 1b-Studie für ZED1227 zur Zöliakie-Therapie bekannt und planen Start der Wirksamkeitsstudie
  • Press release: Dr. Falk Pharma and Zedira announce completion of phase 1b clinical trial of ZED1227 for the treatment of celiac disease and move on to proof of concept study
  • Press Release: Dr. Falk Pharma GmbH and Zedira enter a phase 1b clinical trial for a celiac disease drug
  • Zedira publication: Microbial transglutaminase has a lower deamidation preference than human tissue transglutaminase on a celiac disease relevant wheat gliadin T-cell epitope
  • Press release: Additional subsidy funding for clinical development of a celiac disease drug
  • Pressemitteilung: Zusätzliche Fördermittel für die klinische Entwicklung eines Zöliakie-Medikamentes
  • Press Release: Cooperation between Zedira and Cardiff University - Transglutaminase 6 is the focus of new research into ataxia
  • Press Release: Dr. Falk Pharma and Zedira enter phase I clinical trials for a celiac disease drug
  • Press release: Zedira receives further funding to develop Factor XIIIa-blockers for safe anticoagulation



  • 19th International Celiac Disease Symposium

    14.10.2021 - 17.10.2021
    Sorrento, Italy

  • Gordon Research Conference: Transglutaminases in Human Disease Processes

    12.06.2022 - 17.06.2022
    Mount Snow, USA